DK3081215T3 - Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin - Google Patents

Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin Download PDF

Info

Publication number
DK3081215T3
DK3081215T3 DK16159734.9T DK16159734T DK3081215T3 DK 3081215 T3 DK3081215 T3 DK 3081215T3 DK 16159734 T DK16159734 T DK 16159734T DK 3081215 T3 DK3081215 T3 DK 3081215T3
Authority
DK
Denmark
Prior art keywords
alanine
beta
procedures
compositions
long
Prior art date
Application number
DK16159734.9T
Other languages
English (en)
Inventor
Roger Harris
John Wise
Original Assignee
Natural Alternatives Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural Alternatives Int Inc filed Critical Natural Alternatives Int Inc
Application granted granted Critical
Publication of DK3081215T3 publication Critical patent/DK3081215T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK16159734.9T 2005-05-23 2006-05-23 Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin DK3081215T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68398505P 2005-05-23 2005-05-23
EP06848675.2A EP1883406B1 (en) 2005-05-23 2006-05-23 Compositions and methods for the sustained release of beta-alanine

Publications (1)

Publication Number Publication Date
DK3081215T3 true DK3081215T3 (da) 2020-04-27

Family

ID=38189110

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16159734.9T DK3081215T3 (da) 2005-05-23 2006-05-23 Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK06848675.2T DK1883406T3 (da) 2005-05-23 2006-05-23 Sammensætninger og fremgangsmåder til langvarig frigivelse af beta-alanin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06848675.2T DK1883406T3 (da) 2005-05-23 2006-05-23 Sammensætninger og fremgangsmåder til langvarig frigivelse af beta-alanin

Country Status (8)

Country Link
US (8) US8329207B2 (da)
EP (2) EP1883406B1 (da)
JP (2) JP5336180B2 (da)
KR (2) KR101190791B1 (da)
CN (2) CN106038473A (da)
CA (1) CA2621365C (da)
DK (2) DK3081215T3 (da)
WO (1) WO2007073398A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965596A (en) 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
DK3081215T3 (da) 2005-05-23 2020-04-27 Natural Alternatives Int Inc Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
US7956218B2 (en) * 2007-12-12 2011-06-07 Northern Innovations And Formulations Corp. Organic salts of β-alanine
EP2231588A4 (en) * 2007-12-12 2011-02-09 Northern Innovations And Formulations Corp ORGANIC SALTS OF -ALANINE
JP5519945B2 (ja) * 2009-03-10 2014-06-11 株式会社ファンケル 抗不安剤
WO2011019348A1 (en) * 2009-08-12 2011-02-17 Kneller Bruce W CREATINE β-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
US9414615B2 (en) * 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same
TW201201713A (en) * 2010-04-05 2012-01-16 Abbott Lab Shelf stable nutritional liquids comprising beta alanine
WO2013056048A2 (en) * 2011-10-13 2013-04-18 Abbott Laboratories Nutritional products comprising beta-alanine
AU2013207095B2 (en) * 2012-01-03 2016-09-22 Nestec S.A. Compositions and methods for the stability of reactive amino acids in a food matrix
US8496979B1 (en) * 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
EP2666365A1 (en) * 2012-05-22 2013-11-27 Taminco Treatment of poultry, pigs or fish for reducing the feed conversion ratio.
ITMI20121586A1 (it) * 2012-09-24 2014-03-25 N G C Medical Spa L-carnosina per il trattamento delle miopatia congenita mitocondriale e della sindrome della fatica muscolare cronica
CN103005435B (zh) * 2012-12-13 2014-01-29 北京康比特体育科技股份有限公司 一种抗疲劳、提高速度耐力的组合物及含其制剂
EP2948139B1 (en) * 2013-01-28 2019-06-12 Lopez, Hector, L. Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
US20150057354A1 (en) * 2013-08-20 2015-02-26 Natural Alternatives International, Inc. Method of maintaining or improving tactical performance and cognitive function through dietary supplementation
WO2016138454A1 (en) * 2015-02-27 2016-09-01 Natural Alternatives International, Inc. Methods of improving physiological responses related to post-traumatic stress disorder through dietary supplementation
WO2017053171A1 (en) * 2015-09-25 2017-03-30 Natural Alternatives International, Inc. Methods of improving physiological conditions related to pregnancy and development of offspring through dietary supplementation
CN105663081B (zh) 2015-12-30 2019-08-02 大连医诺生物股份有限公司 微囊化β-丙氨酸
US10529418B2 (en) * 2016-02-19 2020-01-07 Hewlett Packard Enterprise Development Lp Linear transformation accelerators
WO2018226987A1 (en) * 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
EP3991790A4 (en) * 2019-06-28 2023-10-25 Yuki Gosei Kogyo Co., Ltd. MITOCHONDRIAL FUNCTION ACTIVATOR
JP6749665B1 (ja) * 2019-07-18 2020-09-02 株式会社東洋新薬 経口組成物
US11850217B2 (en) 2020-05-20 2023-12-26 Advanced Food Concepts, Inc. Athletic performance enhancement composition using menthol
CN111956780A (zh) * 2020-08-28 2020-11-20 黑龙江现代物联网科技有限公司 一种用鹅肌肽制成降低人体尿酸的饮用水及其制备方法
CN113812635B (zh) * 2021-09-22 2023-12-19 大连医诺生物股份有限公司 微囊化β-丙氨酸、其制备方法及应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966988A (en) * 1971-07-28 1976-06-29 International Flavors & Fragrances Inc. Flavoring compositions and processes utilizing dithiazine compounds
USRE30370E (en) * 1971-11-04 1980-08-12 International Flavors & Fragrances Inc. Flavoring foodstuffs with a thioester
DE2519656A1 (de) * 1974-05-13 1975-11-27 Sandoz Ag Neue peptide und verfahren zu ihrer herstellung
US3934036A (en) * 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
JPS54159393A (en) 1978-06-08 1979-12-17 Ajinomoto Co Inc Polyamino acid-coated activated carbon
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) * 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6016934A (ja) 1983-07-06 1985-01-28 Kaneshiro Nagai 抗腫瘍剤
IT1176983B (it) * 1984-10-16 1987-08-26 Zambon Spa Dipeptidi ad attivita' farmacologica
JPS61204120A (ja) 1985-03-07 1986-09-10 Kaneshiro Nagai 免疫調節剤
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
DE3613758A1 (de) * 1986-04-23 1987-10-29 Consortium Elektrochem Ind Cysteinreiche, (gamma)-glutaminsaeure- und (beta)-alanin-einheiten aufweisende peptide, verfahren zu deren herstellung und ihre verwendung
FR2609893B1 (fr) 1987-01-26 1990-03-30 Rougereau Andre Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique
JPS6442425A (en) 1987-08-11 1989-02-14 Nippon Univ Remedy for cachexia
WO1990006102A1 (en) 1988-09-28 1990-06-14 Peptide Technology Limited Compound and method for the retardation of collagen cross-linking
JPH0395125A (ja) 1989-05-23 1991-04-19 Otsuka Pharmaceut Co Ltd カルシウム代謝改善剤
IT1240336B (it) 1990-03-21 1993-12-07 Setra Composizioni farmaceutiche,dietetiche o veterinarie ad attivita' eumetabolica
JP2873493B2 (ja) 1990-08-09 1999-03-24 理化学研究所 血糖調節剤
JP2873497B2 (ja) 1990-09-03 1999-03-24 理化学研究所 脂質代謝調節剤
US5190775A (en) * 1991-05-29 1993-03-02 Balchem Corporation Encapsulated bioactive substances
WO1993004690A1 (en) 1991-09-09 1993-03-18 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes
JPH0624976A (ja) 1992-07-10 1994-02-01 Rikagaku Kenkyusho 輸液用組成物
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3213666B2 (ja) * 1994-02-28 2001-10-02 治彦 末岡 クレアチン飲料の製造方法
ES2188644T3 (es) * 1994-09-30 2003-07-01 Oreal Utilizacion de una sustancia agonista de un receptor asociado con un canal de cloro en el tratamiento de las arrugas.
JP3595373B2 (ja) 1995-02-20 2004-12-02 治彦 末岡 クレアチン飲料
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
EP0877617A1 (en) * 1996-01-24 1998-11-18 Aliatros Medical A.S. Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid
US6274161B1 (en) * 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
GB9611356D0 (en) 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
ATE208144T1 (de) * 1996-08-12 2001-11-15 Harris Roger C Verfahren und zusammensetzungen zur steigerung der anaerobe leistungsfähigkeit in geweben
US5965596A (en) * 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
DE69838750T2 (de) * 1997-05-16 2008-10-30 Amgen Inc., Thousand Oaks Zeitverzögerte gelzusammensetzungen mit verlängerter wirkstoffverabreichung
US6019999A (en) * 1997-12-03 2000-02-01 Miller; David F. Process for making liposomal ion-exchange whey protein and products thereof
CN1173742C (zh) 1997-12-26 2004-11-03 山之内制药株式会社 缓释药物组合物
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
GB9924650D0 (en) * 1999-10-19 1999-12-22 Marathade Ltd Energy bar
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
WO2001078683A2 (en) 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
JP2002051730A (ja) 2000-08-08 2002-02-19 Nippon Meat Packers Inc スポーツ用食品
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
CA2434156A1 (en) 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
DK1363509T3 (da) 2001-03-02 2007-02-12 Howard Foundation Sammensætninger indeholdende creatin og creatinin
AU2003234146A1 (en) * 2002-04-22 2003-11-03 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US6835397B2 (en) * 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
DK3081215T3 (da) 2005-05-23 2020-04-27 Natural Alternatives Int Inc Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin

Also Published As

Publication number Publication date
KR101190791B1 (ko) 2012-10-12
US9907769B2 (en) 2018-03-06
US8329207B2 (en) 2012-12-11
CA2621365C (en) 2012-09-04
JP5336180B2 (ja) 2013-11-06
US8496958B2 (en) 2013-07-30
KR101275660B1 (ko) 2013-06-17
US8980307B2 (en) 2015-03-17
JP2008542282A (ja) 2008-11-27
KR20080028374A (ko) 2008-03-31
US10828274B2 (en) 2020-11-10
US20150157587A1 (en) 2015-06-11
DK1883406T3 (da) 2016-08-15
US20130142859A1 (en) 2013-06-06
CN101309688A (zh) 2008-11-19
EP1883406A2 (en) 2008-02-06
CN106038473A (zh) 2016-10-26
US20180256528A1 (en) 2018-09-13
US12036196B2 (en) 2024-07-16
US20130030052A1 (en) 2013-01-31
EP1883406B1 (en) 2016-07-06
US20210260005A1 (en) 2021-08-26
US9636315B2 (en) 2017-05-02
KR20120094109A (ko) 2012-08-23
EP3081215B1 (en) 2020-04-01
EP3081215B9 (en) 2020-08-19
US20140017293A1 (en) 2014-01-16
JP2013224310A (ja) 2013-10-31
WO2007073398A3 (en) 2007-09-07
WO2007073398A2 (en) 2007-06-28
US20160354329A1 (en) 2016-12-08
US20090220575A1 (en) 2009-09-03
EP3081215A1 (en) 2016-10-19
CN101309688B (zh) 2016-06-22
EP1883406A4 (en) 2009-11-04
CA2621365A1 (en) 2007-06-28
US8394402B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK1937824T3 (da) Sammensætninger af tRNA og anvendelser deraf
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK1969007T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
DK1856374T3 (da) Sammensætning og fremgangsmåde til fremstilling af et støttemiddel
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK1879566T3 (da) Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK1948695T3 (da) Immunogene sammensætninger og fremgangsmåder til andvendelse
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
DK1831154T3 (da) Fremstilling af pregabalin og relaterede forbindelser
DK2460820T3 (da) PCV2-immunogene sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2029746T3 (da) Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK1891208T3 (da) Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf